Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants
A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of DEB025/Alisporivir in Combination With Peg-IFNα2a and Ribavirin in Hepatitis C Genotype 1 Treatment-naïve Patients
Sponsor: Debiopharm International SA
Listed as NCT01318694, this PHASE3 trial focuses on Hepatitis C and remains completed. Sponsored by Debiopharm International SA, it has been updated 10 times since 2011, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Mar 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Debiopharm International SA
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arlington, United States, Baltimore, United States, Bangkok, Thailand, Barcelona, Spain, Berlin, Germany, Beverly Hills, United States, Bialystok, Poland, Birmingham, United Kingdom, Bologna, Italy, Bradenton, United States and 105 more location s